Canopy Growth stock tumbles after announcing $200 million share sale plan
SYDNEY - Wellnex Life Limited (ASX/AIM:WNX) reported a 40.4% increase in total revenue to $23.6 million for the fiscal year ended June 30, 2025, according to a preliminary financial report released Friday.
The health and wellness company saw its gross profit rise 38.4% to $6.9 million compared to the previous year, while its normalized EBITDA loss improved by 57% to $2.2 million from $5.2 million in fiscal 2024.
Despite the revenue growth, Wellnex recorded a net loss of $15.6 million for the year, which the company said was impacted by $11.7 million in non-cash and one-off expenses primarily related to Pain Away brand operations and corporate activities including its dual listing on the London Stock Exchange’s AIM market.
The company’s net assets increased 85.6% to $11.3 million as of June 30, 2025.
Wellnex noted that its gross margin decreased to 23% in the first half of the fiscal year due to a one-off increase in trade investment, but improved to 37% in the second half following what the company described as "a more disciplined approach to trade investment."
The revenue increase was primarily driven by the company’s brands, including Pain Away, according to the press release statement.
Wellnex indicated it has "many growth initiatives" planned for fiscal 2026 that will "continue to drive revenue growth and build strong margins," including expanding licensing opportunities both domestically and internationally.
The financial results released are unaudited preliminary figures.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.